Current medical treatment for NAFLD/NASH
Current medical treatment for NAFLD/NASH; [Traitement médical de la stéatohépatite métabolique en 2022]
Résumé
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. The high prevalence of NAFLD is related to rising rates of obesity and metabolic syndrome. NAFLD prognosis is most closely linked with fibrosis stage, which can be assessed using non-invasive tests. Therapeutic endpoints include NASH resolution and fibrosis improvement. This hepatic endpoint must be integrated into the overall metabolic issue. Therapeutic strategy is based on lifestyle interventions and weight loss. Indeed, weight loss of 7–10% can reverse liver fibrosis, but adherence to lifestyle changes remains a major problem in real life. There are currently no approved pharmacological treatments for NASH. However, several therapeutic agents are rapidly progressing through the different phases of clinical trials. We provide a summary of recent therapeutic options with most advanced results. © 2023 Société francophone nutrition clinique et métabolisme (SFNCM)